JP7827696B2 - トリフェニルカルシリティック化合物の製剤 - Google Patents

トリフェニルカルシリティック化合物の製剤

Info

Publication number
JP7827696B2
JP7827696B2 JP2023507979A JP2023507979A JP7827696B2 JP 7827696 B2 JP7827696 B2 JP 7827696B2 JP 2023507979 A JP2023507979 A JP 2023507979A JP 2023507979 A JP2023507979 A JP 2023507979A JP 7827696 B2 JP7827696 B2 JP 7827696B2
Authority
JP
Japan
Prior art keywords
weight
tablet formulation
tablet
present
cltx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536667A5 (enExample
JP2023536667A (ja
Inventor
シンハ ウマ
スリダー アナント
プラサド リーナ
コメイリー アリ
Original Assignee
カルシリティクス セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カルシリティクス セラピューティクス，インコーポレイティド filed Critical カルシリティクス セラピューティクス，インコーポレイティド
Publication of JP2023536667A publication Critical patent/JP2023536667A/ja
Publication of JP2023536667A5 publication Critical patent/JP2023536667A5/ja
Priority to JP2026029931A priority Critical patent/JP2026086851A/ja
Application granted granted Critical
Publication of JP7827696B2 publication Critical patent/JP7827696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023507979A 2020-08-04 2021-08-03 トリフェニルカルシリティック化合物の製剤 Active JP7827696B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026029931A JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061050P 2020-08-04 2020-08-04
US63/061,050 2020-08-04
PCT/US2021/044295 WO2022031666A1 (en) 2020-08-04 2021-08-03 Formulations of triphenyl calcilytic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026029931A Division JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Publications (3)

Publication Number Publication Date
JP2023536667A JP2023536667A (ja) 2023-08-28
JP2023536667A5 JP2023536667A5 (enExample) 2024-08-13
JP7827696B2 true JP7827696B2 (ja) 2026-03-10

Family

ID=77431430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507979A Active JP7827696B2 (ja) 2020-08-04 2021-08-03 トリフェニルカルシリティック化合物の製剤
JP2026029931A Pending JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026029931A Pending JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Country Status (13)

Country Link
US (2) US20220040112A1 (enExample)
EP (1) EP4192438A1 (enExample)
JP (2) JP7827696B2 (enExample)
KR (1) KR20230106582A (enExample)
CN (1) CN116648243A (enExample)
AR (1) AR123147A1 (enExample)
AU (1) AU2021320147B2 (enExample)
BR (1) BR112023002107A2 (enExample)
CA (1) CA3188044A1 (enExample)
IL (1) IL300285A (enExample)
MX (1) MX2023001438A (enExample)
TW (1) TWI924683B (enExample)
WO (1) WO2022031666A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) * 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).
WO2024160842A1 (en) 2023-01-30 2024-08-08 Medizinische Universität Wien Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094362A1 (ja) 2003-04-23 2004-11-04 Japan Tobacco Inc. CaSRアンタゴニスト
WO2010110352A1 (ja) 2009-03-26 2010-09-30 日本たばこ産業株式会社 カルボン酸化合物の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
ES2900353T3 (es) * 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
BR112020013073A2 (pt) 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2021029517A1 (en) 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094362A1 (ja) 2003-04-23 2004-11-04 Japan Tobacco Inc. CaSRアンタゴニスト
WO2010110352A1 (ja) 2009-03-26 2010-09-30 日本たばこ産業株式会社 カルボン酸化合物の製造方法

Also Published As

Publication number Publication date
BR112023002107A2 (pt) 2023-03-07
CN116648243A (zh) 2023-08-25
AR123147A1 (es) 2022-11-02
US12357576B2 (en) 2025-07-15
EP4192438A1 (en) 2023-06-14
MX2023001438A (es) 2023-06-15
TW202220642A (zh) 2022-06-01
AU2021320147B2 (en) 2026-07-30
US20220040112A1 (en) 2022-02-10
CA3188044A1 (en) 2022-02-10
JP2026086851A (ja) 2026-05-26
KR20230106582A (ko) 2023-07-13
IL300285A (en) 2023-04-01
JP2023536667A (ja) 2023-08-28
WO2022031666A1 (en) 2022-02-10
US20240074978A1 (en) 2024-03-07
AU2021320147A1 (en) 2023-03-30
TWI924683B (zh) 2026-05-11

Similar Documents

Publication Publication Date Title
EP3641742B1 (en) Hydroxynorketamine for the use in the treatment of depression
DE60221691T3 (de) Tamsulosin tabletten ohne nahrungsmitteleffekt
JP4868695B2 (ja) 崩壊性が良好な経口製剤
US12357576B2 (en) Formulations of triphenyl calcilytic compounds
AU2019321583B2 (en) Formulations of AG10
US20240100011A1 (en) Pediatric formulations of ferric citrate
JP2017214352A (ja) 高負荷、制御放出マグネシウム経口剤形およびそれを作製および使用するための方法
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
US20130165459A1 (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
JP2016514125A (ja) バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
JP2023553274A (ja) ドフェチリド及びメキシレチンを含有する組成物並びにその使用
US8309607B2 (en) Rapid release irbesartan-containing pharmaceutical composition
WO2026088136A1 (en) Methods of treating a neurodegenerative disease
HK40056307A (en) Formulations of ag10
HK40056307B (en) Formulations of ag10
RU2773029C2 (ru) Галеновые композиции органических соединений
BR112015022103B1 (pt) Composição farmacêutica para prevenir ou tratar uma doença cardiovascular e uma doença hiperlipidêmica, ou tratar sinergicamente hipertensão, e, método para preparar uma composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260226

R150 Certificate of patent or registration of utility model

Ref document number: 7827696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150